Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer
- 1School of Public Health, Gansu University of Chinese Medicine , , ,
- 2Department I, Radiation Therapy Center, Gansu Wuwei Tumour Hospital , , ,
- 3Follow-up Office, Gansu Wuwei Tumour Hospital , , ,
Abstract
Objective: To investigate the clinical efficacy, safety and prognostic influencing factors of carbon ion radiotherapy (CIRT) in patients with limited-stage small-cell lung cancer (LS-SCLC).
Methods: The clinical data of 39 patients with LS-SCLC who received CIRT from June 2020 to August 2026 were retrospectively analyzed. Survival outcomes and adverse reactions were evaluated, and Cox regression was used to analyze prognostic factors.
Results: All patients completed the treatment. The 3-month objective response rate (ORR) was 64.10%. The 1- and 2-year local control rates were both 91.2%. The 1- and 2-year overall survival (OS) rates were 91.65% and 62.45%, with a median OS of 44 months. The 1- and 2-year progression-free survival (PFS) rates were 72.00% and 47.77%, with a median PFS of 24 months. Serum levels of NSE, CYFRA21-1, SCC and CEA decreased significantly after treatment. Acute treatment-related adverse reactions were mainly grade I-II and could be relieved after symptomatic treatment. Stratified Cox regression indicated that KPS score was an independent protective factor for OS. Univariate analysis suggested that the magnitude of post-treatment reduction in SCC and CYFRA21-1 was potentially associated with survival outcomes.
Conclusion: CIRT achieves favorable local tumor control with low acute radiotherapy-related toxicity, and can serve as an alternative therapeutic option for LS-SCLC. This is a single-center, small-sample retrospective study, and the conclusions regarding efficacy and prognosis need to be further verified in larger-sample cohorts.
Related
- Ommaya Reservoir-Based Cerebrospinal Fluid Chemotherapy for Leptomeningeal Metastasis in the Era of Targeted Therapy: Safety, Survival, and Exploratory Prognostic Factors from a Single-Center Cohort
- Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors.
- Prognostic Factors and a Polymetastasis-Free Survival Nomogram in Oligometastatic Head and Neck Squamous Cell Carcinoma Treated with Local Ablative Therapy.
- Prognostic factors and survival outcomes of multimodal treatment in sinonasal neuroendocrine tumors in a population based SEER analysis
- Analysis of prognostic factors for survival after curative resections of clear-cell renal cell carcinoma based on Bayesian networks
BibTeX
@article{liang2026survival,
title = {{Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer}},
author = {Xuexue Liang and Qinli Gong and Yihe Zhang and Ling Tian and Xiaoli Zhao and Bole Wang and Zhenglin Li and Pengqing Li and Yancheng Ye and Yanshan Zhang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1898779},
url = {https://europepmc.org/article/PMC/PMC13668746},
note = {CC BY},
}
RIS
TY - JOUR
TI - Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer
AU - Xuexue Liang
AU - Qinli Gong
AU - Yihe Zhang
AU - Ling Tian
AU - Xiaoli Zhao
AU - Bole Wang
AU - Zhenglin Li
AU - Pengqing Li
AU - Yancheng Ye
AU - Yanshan Zhang
PY - 2026
DA - 2026/10/01
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1898779
UR - https://europepmc.org/article/PMC/PMC13668746
AB - Objective: To investigate the clinical efficacy, safety and prognostic influencing factors of carbon ion radiotherapy (CIRT) in patients with limited-stage small-cell lung cancer (LS-SCLC). Methods: The clinical data of 39 patients with LS-SCLC who received CIRT from June 2020 to August 2026 were retrospectively analyzed. Survival outcomes and adverse reactions were evaluated, and Cox regression was used to analyze prognostic factors. Results: All patients completed the treatment. The 3-month objective response rate (ORR) was 64.10%. The 1- and 2-year local control rates were both 91.2%. The 1- and 2-year overall survival (OS) rates were 91.65% and 62.45%, with a median OS of 44 months. The 1- and 2-year progression-free survival (PFS) rates were 72.00% and 47.77%, with a median PFS of 24 months. Serum levels of NSE, CYFRA21-1, SCC and CEA decreased significantly after treatment. Acute treatment-related adverse reactions were mainly grade I-II and could be relieved after symptomatic treatment. Stratified Cox regression indicated that KPS score was an independent protective factor for OS. Univariate analysis suggested that the magnitude of post-treatment reduction in SCC and CYFRA21-1 was potentially associated with survival outcomes. Conclusion: CIRT achieves favorable local tumor control with low acute radiotherapy-related toxicity, and can serve as an alternative therapeutic option for LS-SCLC. This is a single-center, small-sample retrospective study, and the conclusions regarding efficacy and prognosis need to be further verified in larger-sample cohorts.
SN - 2234-943X
ER -